Irkutsk anti-plague institute death prompts quarantines and conflicting official accounts.
|Videos|May 19, 2020
Contagion Live News Network: Coronavirus Briefing for May 19, 2020
Author(s)Contagion® Editorial Staff
A daily news update on our COVID-19 coverage.
Advertisement
Hello and thank you for joining Contagion. I’m assistant editor Grant Gallagher, here with an infectious disease news brief.
Researchers and epidemiologists are working tirelessly to understand clusters that shed new insight into transmission dynamics.A recent CDC Morbidity and Mortality Weekly Report or “MMWR” focused on
Today we also shared an interview with Dr. Adam Brufsky, an oncologist who has worked with infectioius disease researchers to contribute new theories on COVID. In this second part of our interview, Dr. Brufsky moves from talking about glycosolation of the SARS-CoV-2 spike protein to emerging evidence about the potential for multiple strains of the coronavirus.
And as a reminder, yesterday we shared an interview with Dr. Armand Balboni, CEO of a biotechnology company that’s working with FUJIFILM Toyama Chemical on its favipiravir treatment, which is approved in Japan as an antiviral, on a new front for the drug — the global search for a pandemic treatment that can both prevent and combat COVID-19
For more on these stories and other infectious disease news, visit contagionlive.com.
Advertisement
Related to this article
A laboratory technician at a Siberian anti-plague institute has died of pneumonia of unknown cause, prompting quarantines and contact monitoring while Russian officials stop short of confirming plague.
A study finding clesrovimab comparable to palivizumab in protecting at-risk infants in their first RSV season was extended to demonstrate clesrovimab effective and well-tolerated when administered in their second season.
Lori Handy, MD, provides guidance in these areas including presentation before rash onset, when patients should be considered for the inpatient setting, and what treatment looks like.
Jason Pogue, PharmD, BCPS, BCIDP, contextualizes preliminary data looking at this trial and other extended-spectrum beta-lactamase (ESBL) studies, which reopens the debate around carbapenem-sparing treatment options.
In the phase 3 LIBERTY study, the investigational monoclonal antibody, VYD2311, had significantly fewer adverse events than an mRNA COVID-19 vaccine, and it did not blunt vaccine-induced neutralizing titers when the two were given together.
With a significant increase in rabies exposures this year, Rodney Rohde, PhD, talks about seeking medical attention after animal interactions as well as clinical treatment when people have been bit or scratched.
In the first episode of our new series looking at the food safety network, Lynette Johnston, PhD, offers insights into how the federal government surveillance infrastructure operates and how epidemiologists serve as food detectives in determining bacterial pathogens and potential foodborne outbreaks.
Advertisement
Advertisement